151 related articles for article (PubMed ID: 36760876)
1. Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series.
Qi X; Zhang ZF; Gao XS; Qin SB; Bai Y; Yu W; He Q; Fan Y; Zhang JH; Jiang Y; He ZS; Li HZ
Transl Androl Urol; 2023 Jan; 12(1):128-138. PubMed ID: 36760876
[TBL] [Abstract][Full Text] [Related]
2. Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study.
Bai Y; Gao XS; Qin SB; Chen JY; Su MM; Liu Q; Qin XB; Ma MW; Zhao B; Gu XB; Xie M; Cui M; Qi X; Li XY
Onco Targets Ther; 2018; 11():2571-2579. PubMed ID: 29780250
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
5. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
10. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
12. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
14. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
Turina CB; Coleman DJ; Thomas GV; Fung AW; Alumkal JJ
Cureus; 2019 Jul; 11(7):e5197. PubMed ID: 31565603
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization.
Lee HL; Tsai JT; Chen CY; Lin YC; Ho CB; Ting LL; Kuo CC; Lai IC; Lin CY; Tang JH; Huang YM; Kao WY; Cheng SW; Shen CN; Chen SW; Chiou JF
Ther Adv Med Oncol; 2019; 11():1758835919889002. PubMed ID: 31839809
[TBL] [Abstract][Full Text] [Related]
17. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
18. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
19. Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience.
Sánchez-Iglesias ÁL; Morillo-Macías V; Santafé-Jiménez A; Ferrer-Albiach C
Radiat Oncol J; 2022 Sep; 40(3):192-199. PubMed ID: 36200308
[TBL] [Abstract][Full Text] [Related]
20. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.
Li S; Shen L
J Cancer; 2020; 11(17):5056-5068. PubMed ID: 32742453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
